PSB-603 is an antagonist of the adenosine A2B receptor (Ki = 0.553 nM).1 It is selective for adenosine A2B over A1, A2A, and A3 receptors (Kis = >10,000 nM). It reduces intracellular calcium concentrations in Jurkat T cells expressing the human A2B receptor (IC50 = 1.13 nM). PSB-603 reduces Zika viral plaque formation (IC50 = 43.8 nM) without affecting cell viability of A549 cells when used at concentrations up to 1 µM.2 In vivo, PSB-603 (0.25 µg/head, i.p.) delays tumor growth and reduces tumor volume and the number of pulmonary metastases in the B16 mouse model of melanoma via inhibition of induction of regulatory T cells.3
WARNING This product is not for human or veterinary use.